A detailed history of Strategic Investment Advisors transactions in Exelixis, Inc. stock. As of the latest transaction made, Strategic Investment Advisors holds 33,343 shares of EXEL stock, worth $1.39 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
33,343
Previous 33,343 -0.0%
Holding current value
$1.39 Million
Previous $1.38 Million -0.0%
% of portfolio
0.11%
Previous 0.03%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$36.22 - $46.25 $1 Million - $1.28 Million
27,659 Added 486.61%
33,343 $1.38 Million
Q2 2025

Aug 14, 2025

SELL
$34.13 - $46.26 $14,061 - $19,059
-412 Reduced 6.76%
5,684 $250,000
Q1 2025

Apr 23, 2025

BUY
$32.38 - $39.16 $197,388 - $238,719
6,096 New
6,096 $225,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $13.4B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Strategic Investment Advisors Portfolio

Follow Strategic Investment Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Investment Advisors , based on Form 13F filings with the SEC.

News

Stay updated on Strategic Investment Advisors with notifications on news.